SCHEMBL1120016

SCHEMBL1120016

CCN(CC)C1CCN(C(C(=O)OC)c2ccc(C=CC(=O)N(NC(=O)OC(C)(C)C)c3ccccc3)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 6/20 0.38
HTR2A P28223 3/20 0.35
HTR2C P28335 3/20 0.35
HTR2B P41595 3/20 0.35
SIGMAR1 Q99720 3/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 1/20 0.34
LTB4R Q15722 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
DRD2 P14416 2/20 0.33
NR1H4 Q96RI1 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
CTSL P07711 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119719 0.94 TRPM8 (0.37) TRPM8HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL1119726 0.88 TRPM8 (0.41) TRPM8HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL1120015 0.83 RAB9A (0.38) TRPM8MEN1ALDH1A1LMNAKMT2A
SCHEMBL1120014 0.83 RAB9A (0.38) TRPM8MEN1ALDH1A1LMNAKMT2A
SCHEMBL1120046 0.82 TRPM8 (0.40) TRPM8HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL1119717 0.78 EGFR (0.37) TRPM8MEN1ALDH1A1LMNAKMT2A
SCHEMBL1119718 0.78 EGFR (0.37) TRPM8MEN1ALDH1A1LMNAKMT2A
SCHEMBL3226499 0.77 TRPM8 (0.36) TRPM8HTR2AKMT2ANR1H4PPARG
SCHEMBL1119874 0.77 TRPM8 (0.44) TRPM8MEN1ALDH1A1LMNAKMT2A
SCHEMBL3230458 0.77 BCL9 (0.38) TRPM8MEN1LMNAKMT2ANR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999000-B2 N-(2-amino-phenyl)-acrylamides HOFFMANN-LA ROCHE INC. (US) 2011-08-16 US disclosed
EP-2280940-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES F. Hoffmann-La Roche AG (CH) 2011-02-09 EP disclosed
WO-2009138338-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2009-11-19 WO disclosed
US-20090286848-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES HOFFMANN-LA ROCHE INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286848-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES MKI67, CCNA2, CCNA1 TRPM8 4248/4885HTR2A 1110/4885HTR2C 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.